Skip to main
  1. Stocks
  2. Mirum Pharmaceuticals Inc
  3. Forecast
MIRM

MIRM Stock Forecast & Price Target

MIRM Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 31%
Buy 69%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Mirum Pharmaceuticals is viewed favorably because it continues to deliver a strong commercial beat, with 3Q26 Livmarli sales of $133.4M and total net product sales of $186M, while management raised FY26 product guidance to $715M–$720M and expects $10–$15M sequential quarterly revenue growth through 2027. Its outlook is further supported by a diversified late-stage pipeline, including positive Phase 3 EXPAND data for broader cholestatic diseases, the October launch of Atebrioz in FOP, and brelovitug’s positive AZURE-1 results with 4Q26 data and a 1H27 BLA path ahead. The company also remains well capitalized with about $500M in cash and is expected to become cash flow positive next year, reducing financing risk while multiple catalysts approach.

Bears say

Mirum Pharmaceuticals is facing a more fragile fundamental setup because its oral-solution LOE has been moved to 2035, while formulation and method-of-treatment patents may expire in 2031–2032 and the 2040 dosing patents could still be vulnerable to obviousness challenges. The company also carries meaningful execution risk across several unproven indications, since BA, PSC, and PBC all require additional clinical studies and regulatory pathways that are novel or uncharted, with no drugs approved for BA or PSC today. At the same time, greater-than-expected operating expenses and cash burn could force more frequent or less favorable equity raises, while Bylvay and other iBAT inhibitor programs intensify competitive pressure on Livmarli and the broader pipeline.

MIRM has been analyzed by 13 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 69% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Mirum Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

MIRM Analyst Forecast & Price Prediction

Get the latest MIRM stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in MIRM

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Mirum Pharmaceuticals Inc (MIRM) Forecast

Analysts have given MIRM a Buy based on their latest research and market trends.

According to 13 analysts, MIRM has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $155.15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $155.15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Mirum Pharmaceuticals Inc (MIRM)


MIRM Analyst Forecast & Price Prediction

Get the latest MIRM stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in MIRM

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover MIRM stock data and trends